Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding.

MLA

Arai, Jun, et al. “Leukotriene Receptor Antagonists Enhance HCC Treatment Efficacy by Inhibiting ADAMs and Suppressing MICA Shedding.” Cancer Immunology, Immunotherapy : CII, vol. 70, no. 1, Jan. 2021, pp. 203–13. EBSCOhost, https://doi.org/10.1007/s00262-020-02660-2.

APA

Arai, J., Goto, K., Otoyama, Y., Nakajima, Y., Sugiura, I., Kajiwara, A., Tojo, M., Ichikawa, Y., Uozumi, S., Shimozuma, Y., Uchikoshi, M., Sakaki, M., Nozawa, H., Nakagawa, R., Muroyama, R., Kato, N., & Yoshida, H. (2021). Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding. Cancer Immunology, Immunotherapy : CII, 70(1), 203–213. https://doi.org/10.1007/s00262-020-02660-2

Chicago

Arai, Jun, Kaku Goto, Yumi Otoyama, Yoko Nakajima, Ikuya Sugiura, Atsushi Kajiwara, Masayuki Tojo, et al. 2021. “Leukotriene Receptor Antagonists Enhance HCC Treatment Efficacy by Inhibiting ADAMs and Suppressing MICA Shedding.” Cancer Immunology, Immunotherapy : CII 70 (1): 203–13. doi:10.1007/s00262-020-02660-2.